非小细胞肺癌患者中 EML4-ALK 易位的范式转变。
The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation.
机构信息
Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.
出版信息
Int J Mol Sci. 2022 Jun 30;23(13):7322. doi: 10.3390/ijms23137322.
The severe prognosis linked with a lung cancer diagnosis has changed with the discovery of oncogenic molecularly driven subgroups and the use of tailored treatment. ALK-translocated advanced lung cancer is the most interesting model, having achieved the longest overall survival. Here, we report the most important paradigmatic shifts in the prognosis and treatment for this subgroup population occurred among lung cancer.
与肺癌诊断相关的严重预后已经随着致癌分子驱动亚组的发现和针对性治疗的应用而改变。ALK 易位的晚期肺癌是最有趣的模型，已经实现了最长的总生存期。在这里，我们报告了肺癌中这种亚组人群的预后和治疗方面最重要的范式转变。
Zotero 插件